Enveric Biosciences (ENVB) Liabilities and Shareholders Equity (2010 - 2026)

Enveric Biosciences has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $5.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 8.22% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.5 million (down 2.62% YoY) and the FY2025 annual result came in at $5.1 million, up 65.32% from the prior year.
• Liabilities and Shareholders Equity advanced to $5.5 million in Q1 2026 per ENVB's latest filing, from $5.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $32.2 million in Q1 2022 and troughed at $3.1 million in Q4 2024.
• A 5-year average of $11.4 million and a median of $6.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity tumbled 78.55% in 2023, then surged 65.32% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $19.6 million in 2022, then sank by 78.01% to $4.3 million in 2023, then dropped by 28.31% to $3.1 million in 2024, then soared by 65.32% to $5.1 million in 2025, then increased by 8.35% to $5.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.5 million, $5.1 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.